ATE135699T1 - 4,5,6-substituierte 2-pyrimidinamine - Google Patents

4,5,6-substituierte 2-pyrimidinamine

Info

Publication number
ATE135699T1
ATE135699T1 AT87100277T AT87100277T ATE135699T1 AT E135699 T1 ATE135699 T1 AT E135699T1 AT 87100277 T AT87100277 T AT 87100277T AT 87100277 T AT87100277 T AT 87100277T AT E135699 T1 ATE135699 T1 AT E135699T1
Authority
AT
Austria
Prior art keywords
substituted
pyrimidinamines
phenyl
disclosure describes
describes novel
Prior art date
Application number
AT87100277T
Other languages
English (en)
Inventor
Lawrence Wayne Torley
Bernard B Johnson
John Paul Dusza
Original Assignee
American Cyanamid Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25224278&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE135699(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by American Cyanamid Co filed Critical American Cyanamid Co
Application granted granted Critical
Publication of ATE135699T1 publication Critical patent/ATE135699T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Photoreceptors In Electrophotography (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Dental Preparations (AREA)
AT87100277T 1986-01-13 1987-01-12 4,5,6-substituierte 2-pyrimidinamine ATE135699T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81795186A 1986-01-13 1986-01-13

Publications (1)

Publication Number Publication Date
ATE135699T1 true ATE135699T1 (de) 1996-04-15

Family

ID=25224278

Family Applications (1)

Application Number Title Priority Date Filing Date
AT87100277T ATE135699T1 (de) 1986-01-13 1987-01-12 4,5,6-substituierte 2-pyrimidinamine

Country Status (18)

Country Link
EP (1) EP0233461B2 (de)
JP (1) JPH0780857B2 (de)
KR (1) KR900004693B1 (de)
AT (1) ATE135699T1 (de)
AU (2) AU591223B2 (de)
BR (1) BR1100989A (de)
CA (1) CA1320201C (de)
DE (1) DE3751742T3 (de)
DK (1) DK171251B1 (de)
ES (1) ES2087056T3 (de)
FI (1) FI91150C (de)
GR (1) GR3019455T3 (de)
HU (1) HU198708B (de)
IE (1) IE74202B1 (de)
NZ (1) NZ218924A (de)
PH (1) PH25056A (de)
SG (1) SG47583A1 (de)
ZA (1) ZA87219B (de)

Families Citing this family (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4966622A (en) * 1988-04-12 1990-10-30 Ciba-Geigy Corporation N-phenyl-N-pyrimidin-2-ylureas
FR2632521B1 (fr) * 1988-06-10 1990-09-14 Rhone Poulenc Sante Nouveaux derives de la phenothiazine, leur preparation et les compositions pharmaceutiques qui les contiennent
GB8903592D0 (en) * 1989-02-16 1989-04-05 Boots Co Plc Therapeutic agents
IE62023B1 (en) * 1989-01-02 1994-12-14 Boots Co Plc Therapeutic agents
IN172842B (de) * 1990-05-17 1993-12-11 Boots Pharmaceuticals Limited
CN1037346C (zh) * 1990-06-29 1998-02-11 布茨公司 降血糖的脒类和胍类的制备方法
US5270319A (en) * 1991-09-09 1993-12-14 Warner-Lambert Company 5-hydroxy-2-pyrimidinylmethylene derivatives useful as antiinflammatory agents
US5162328A (en) * 1991-12-31 1992-11-10 American Cyanamid Company N-[3-[2-(1H-imidazol-1-yl)ethoxy]phenyl]-4-(2-thienyl)-2-pyrimidinamine and pharmacologically acceptable salts
US5196431A (en) * 1992-02-24 1993-03-23 Warner-Lambert Company 2-substituted amino-4, 6-di-tertiary-buthyl-5-hydroxy-1, 3-pyrimidines as antiinflammatory agents
US5220025A (en) * 1992-02-24 1993-06-15 Warner-Lambert Company 2-substituted amino-4, 6-di-tertiary-butyl-5-hydroxy-1, 3-pyrimidines as antiinflammatory agents
TW225528B (de) * 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
GB9212673D0 (en) * 1992-06-15 1992-07-29 Celltech Ltd Chemical compounds
US5516775A (en) * 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
GB9222253D0 (en) * 1992-10-23 1992-12-09 Celltech Ltd Chemical compounds
GB9304919D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
GB9304920D0 (en) * 1993-03-10 1993-04-28 Celltech Ltd Chemical compounds
DK0672041T3 (da) * 1993-10-01 2002-02-25 Novartis Ag Farmakologisk aktive pyridinderivater og fremgangsmåder til fremstilling deraf
EP0672035A1 (de) * 1993-10-01 1995-09-20 Novartis AG Pyrimidinaminderivate und verfahren zu deren herstellung
US5543520A (en) * 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
DE69434721T2 (de) * 1993-10-01 2006-11-09 Novartis Ag Pharmacologisch wirksame pyrimidinderivate und verfahren zu deren herstellung
ATE260911T1 (de) * 1993-12-22 2004-03-15 Celltech R&D Ltd Trisubstituierte phenyl-derivate, verfahren zu deren herstellung und deren verwendung als phosphodiesterase (typ iv) hemmstoffe
GB9326600D0 (en) * 1993-12-22 1994-03-02 Celltech Ltd Chemical compounds
US6245774B1 (en) 1994-06-21 2001-06-12 Celltech Therapeutics Limited Tri-substituted phenyl or pyridine derivatives
US5786354A (en) * 1994-06-21 1998-07-28 Celltech Therapeutics, Limited Tri-substituted phenyl derivatives and processes for their preparation
GB9412573D0 (en) * 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412571D0 (en) 1994-06-22 1994-08-10 Celltech Ltd Chemical compounds
GB9412672D0 (en) * 1994-06-23 1994-08-10 Celltech Ltd Chemical compounds
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9526245D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526246D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
GB9526243D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Chemical compounds
ZA9610687B (en) * 1995-12-22 1997-09-29 Smithkline Beecham Corp Novel synthesis.
JP2000506532A (ja) 1996-03-13 2000-05-30 スミスクライン・ビーチャム・コーポレイション サイトカイン介在疾患の治療にて有用な新規ピリミジン化合物
GB9608435D0 (en) * 1996-04-24 1996-06-26 Celltech Therapeutics Ltd Chemical compounds
GB9619284D0 (en) * 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
GB9625184D0 (en) * 1996-12-04 1997-01-22 Celltech Therapeutics Ltd Chemical compounds
WO1998028281A1 (en) 1996-12-23 1998-07-02 Celltech Therapeutics Limited Fused polycyclic 2-aminopyrimidine derivatives, their preparation and their use as protein tyrosine kinase inhibitors
GB9705361D0 (en) * 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
GB9713087D0 (en) * 1997-06-20 1997-08-27 Celltech Therapeutics Ltd Chemical compounds
AU764479B2 (en) * 1998-10-29 2003-08-21 Bristol-Myers Squibb Company Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme
US6239279B1 (en) 1998-12-16 2001-05-29 Smithkline Beecham Corporation Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
US6316444B1 (en) 1999-06-30 2001-11-13 Merck & Co., Inc. SRC kinase inhibitor compounds
WO2001000207A1 (en) * 1999-06-30 2001-01-04 Merck & Co., Inc. Src kinase inhibitor compounds
DE60006541D1 (de) 1999-06-30 2003-12-18 Merck & Co Inc Src-kinase hemmende verbindungen
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
MXPA02007957A (es) * 2000-02-17 2002-11-29 Amgen Inc Inhibidores de cinasas.
HUP0300382A3 (en) 2000-03-29 2006-11-28 Cyclacel Ltd 2-substituted 4-heteroaryl-pyrimidines and their use in the treatmetn of proliferative disorders and pharmaceutical compositions containing the compounds
US7429599B2 (en) * 2000-12-06 2008-09-30 Signal Pharmaceuticals, Llc Methods for treating or preventing an inflammatory or metabolic condition or inhibiting JNK
US7122544B2 (en) * 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
ES2316546T3 (es) * 2001-02-20 2009-04-16 Astrazeneca Ab 2-arilamino-pirimidinas para el tratamiento de trastornos asociados a gsk3.
GB0107901D0 (en) * 2001-03-29 2001-05-23 Cyclacel Ltd Anti-cancer compounds
EP1430051B1 (de) 2001-09-28 2006-12-27 Cyclacel Limited N-(4-(4-methylthiazol-5-yl)pyrimidin-2-yl)-n-phenylamine als antiproliferative verbindungen
BR0213792A (pt) 2001-11-01 2004-12-07 Janssen Pharmaceutica Nv Heteroaril aminas como inibidores de glicogênio sintase cinase 3beta (inibidores de gsk3)
IL161663A0 (en) * 2001-11-01 2004-09-27 Janssen Pharmaceutica Nv AMINOBENZAMIDE DERIVATIVES AS GLYCOGEN SYNTHASE KINASE 3beta INHIBITORS
AR038368A1 (es) 2002-02-01 2005-01-12 Novartis Ag Compuestos n-pirimidin-2-il-aminas sustituidas como inhibidores de ige, una composicion farmaceutica y el uso de dichos compuestos para la preparacion de un medicamento
GB0222514D0 (en) 2002-09-27 2002-11-06 Novartis Ag Organic compounds
GB0229581D0 (en) * 2002-12-19 2003-01-22 Cyclacel Ltd Use
ES2403558T3 (es) 2004-08-27 2013-05-20 Cyclacel Limited Inhibidores purínicos y pirimidínicos de CDK y su uso para el tratamiento de enfermedades autoinmunitarias
WO2006066172A1 (en) 2004-12-17 2006-06-22 Amgen, Inc. Aminopyrimidine compounds and methods of use
GB0500492D0 (en) * 2005-01-11 2005-02-16 Cyclacel Ltd Compound
GB0520958D0 (en) 2005-10-14 2005-11-23 Cyclacel Ltd Compound
JP2009519218A (ja) 2005-11-03 2009-05-14 エスジーエックス ファーマシューティカルズ、インコーポレイテッド ピリミジニル−チオフェンキナーゼモジュレータ
AU2007336933A1 (en) * 2006-12-22 2008-07-03 Novartis Ag Heteroaryl-heteroaryl compounds as CDK inhibitors for the treatment of cancer, inflammation and viral infections
EP2200436B1 (de) * 2007-09-04 2015-01-21 The Scripps Research Institute Substituierte pyrimidinylamine als proteinkinasenhemmer
WO2009087127A1 (en) 2008-01-11 2009-07-16 F. Hoffmann-La Roche Ag Modulators for amyloid beta
KR101247840B1 (ko) 2008-02-22 2013-03-26 에프. 호프만-라 로슈 아게 아밀로이드 베타 조절제
JP5502089B2 (ja) 2008-10-09 2014-05-28 エフ．ホフマン−ラ ロシュ アーゲー アミロイドβのモジュレーター
WO2010052199A1 (en) 2008-11-10 2010-05-14 F. Hoffmann-La Roche Ag Heterocyclic gamma secretase modulators
US8513242B2 (en) 2008-12-12 2013-08-20 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
US8486967B2 (en) 2010-02-17 2013-07-16 Hoffmann-La Roche Inc. Heteroaryl substituted piperidines
US8334292B1 (en) 2010-06-14 2012-12-18 Cystic Fibrosis Foundation Therapeutics, Inc. Pyrimidine compounds and methods of making and using same
WO2013035102A1 (en) 2011-09-05 2013-03-14 Natco Pharma Limited Processes for the preparation of imatinib base and intermediates thereof
RU2486180C1 (ru) * 2011-11-02 2013-06-27 Общество с ограниченной ответственностью "ТехноХим" (ООО "ТехноХим") Способ получения 2-ариламино-4-гетарилпиримидинов
WO2014055972A2 (en) * 2012-10-05 2014-04-10 The Regents Of The University Of California A new chemical entity useful for treating various diseases
CN114181199B (zh) * 2020-09-15 2023-09-26 成都赜灵生物医药科技有限公司 2，4-二取代嘧啶衍生物及其制备方法和用途
WO2025160033A1 (en) * 2024-01-22 2025-07-31 The Trustees Of Indiana University Lyn modulators for treatment of neurodegenerative disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB735702A (en) * 1952-03-18 1955-08-24 Wellcome Found Improvements in and relating to 2,4-diaminopyrimidines and methods of making the same
US4512993A (en) * 1983-07-25 1985-04-23 Sterling Drug Inc. 4(Or 5)-(pyridinyl)-2-pyrimidinamines and cardiotonic use thereof
US4504482A (en) * 1983-07-28 1985-03-12 Sterling Drug Inc. [5(or 4)-(Pyridinyl)-2-pyrimidinyl]ureas and cardiotonic use thereof
EP0164204A1 (de) * 1984-05-12 1985-12-11 FISONS plc Pharmazeutisch nützliche Pyrimidine
GB8412184D0 (en) * 1984-05-12 1984-06-20 Fisons Plc Biologically active nitrogen heterocycles
US4725600A (en) † 1984-07-13 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent
JPS62501632A (ja) * 1985-02-05 1987-07-02 ジ・アップジョン・カンパニ− ４−置換−６−アリ−ルピリミジン化合物
US4711888A (en) * 1985-07-24 1987-12-08 Pfizer Inc. Hydroxy and alkoxy pyrimidines

Also Published As

Publication number Publication date
PH25056A (en) 1991-01-28
AU6751887A (en) 1987-07-16
ES2087056T3 (es) 1996-07-16
GR3019455T3 (en) 1996-06-30
EP0233461B2 (de) 2002-05-29
DK171251B1 (da) 1996-08-12
FI870113A0 (fi) 1987-01-13
CA1320201C (en) 1993-07-13
DK15187D0 (da) 1987-01-13
ZA87219B (en) 1987-08-26
AU5057890A (en) 1990-07-26
FI91150B (fi) 1994-02-15
DE3751742T3 (de) 2002-11-21
SG47583A1 (en) 1998-04-17
BR1100989A (pt) 1999-11-09
EP0233461B1 (de) 1996-03-20
FI91150C (fi) 1994-05-25
HUT43582A (en) 1987-11-30
AU621461B2 (en) 1992-03-12
FI870113A7 (fi) 1987-07-14
NZ218924A (en) 1990-04-26
JPS62223177A (ja) 1987-10-01
EP0233461A2 (de) 1987-08-26
EP0233461A3 (en) 1988-05-25
DE3751742D1 (de) 1996-04-25
DE3751742T2 (de) 1996-11-21
AU591223B2 (en) 1989-11-30
DK15187A (da) 1987-07-14
KR900004693B1 (ko) 1990-07-02
JPH0780857B2 (ja) 1995-08-30
IE74202B1 (en) 1997-07-16
KR870007154A (ko) 1987-08-17
IE870074L (en) 1987-07-13
HU198708B (en) 1989-11-28

Similar Documents

Publication Publication Date Title
ATE135699T1 (de) 4,5,6-substituierte 2-pyrimidinamine
ATE82499T1 (de) Okulare hypotensivagenzien.
DE3764686D1 (de) N,n'-dihalo-2-imidazolidinone.
DE3783669D1 (de) Alpha-aryl-alpha-phenethyl-1h-1,2,4-triazol-1-propan-nitrile.
FI870192A0 (fi) Nya tieno-1,4-diazepiner.
FI875619A0 (fi) 6-benzoxazinyl- och 6-benzotiazonyl-2,3,4,5-tetrahydropyridazin-3-oner.
DE3783176D1 (de) Bis-dioxopiperazin-abkoemmlinge.
DE3787112D1 (de) Menschliche Pankreaselastase I.
IT1233410B (it) Disposizione circuitale per filatoi o ritorcitoi con comando indipendente.
DE3874929D1 (de) N-silyl-substituierte 1-sila-2-azacyclopentane.
FI883266A0 (fi) 4-aminosubstituerade 1,2-dihydronaftalenderivat.
FI883088A0 (fi) Nya 3',4'-dikvaevesubstituerade epipodofyllotoxinglukosidderivat.
FI875397A0 (fi) Substituerade aminometyl-5,6,7,8 -tetrahydronaftyl-oxiaettikasyror, nya mellanprodukter, foerfarande foer deras framstaellning samt deras anvaendning i laekemedel.
FI881899A7 (fi) Nya 2 ,16 -diaminoandrostaner.
MX9203684A (es) Benzotiazepinas.
ATE68486T1 (de) 1-((2-fluorophenyl)(4-fluorophenyl)phenylmethyl - 1h-imidazol.
FI882943L (fi) Pneumatisk, med slagverkan, saerskilt med ett slag arbetande anordning.
DE3777600D1 (de) Substituierte 1,3,4-oxathiazol-2-one-stabilisatoren.
FI914395A0 (fi) Nya 5,6-substituerade 2,4-kinazo- lindiaminer.
DE3761091D1 (de) 2,6-dimethyl-p-benzochinontetraalkylketale.
IT8741520A0 (it) 2-osso-4-(2'-difluorometiltiofenil)-5-metassicarbonil-6-metil-1,2,3,4tetraidropirimidina.
IT8619804A0 (it) 2,3-diidro-1,4-benzodiossini 2,2-disostituiti ad attivita'ipotensiva.
ES2014286B3 (es) N-benzoilo-n'-83,5-dicloro-2 fenoro-4-triflurometilo-fenoxi)-fenilo)-carbomida.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties